Compare Summit Therapeutics Inc (SMMT) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Wendys Co — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while Wendys Co trades at $6.23 (market cap $1.19B). The key difference: Summit Therapeutics Inc is far larger — about 11.5× Wendys Co's market cap, and Wendys Co pays a 4.49% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Wendys Co for 77 Days on average.
| SMMT | WEN | |
|---|---|---|
Market Cap | $13.71B | $1.19B |
Volume | 6,173,057 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.38 | $9.33 |
52-Week Low | $12.43 | $6.10 |
Typical Hold Time | 16 Days | 77 Days |
Enterprise Value | $13.04B | $4.92B |
Dividend Yield | — | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Wendy's (WEN) trades at $6.22, up 1.8% today but remains in a bearish technical trend with declining fundamentals. Revenue has stagnated around $2.2B, while net income fell to $165M in 2025, with a projected drop to $126M in 2026. The stock appears undervalued with a P/E of 9.45 and P/S of 0.54, but faces headwinds from a major franchisee bankruptcy and six consecutive quarters of same-store sales declines.
The outlook is cautious due to operational challenges and high debt, though the low valuation and consistent dividend offer some support. Analyst consensus is a 'Hold' with a $7.58 price target, reflecting skepticism about near-term recovery. Key risks include competitive pressure, execution missteps, and macroeconomic strain on consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
